Advances in Clinical and Experimental Medicine最新文献

{"title":"Examination of 6 and 12 month follow-up of calcium hydroxide and calcium silicate materials used in direct and indirect pulp capping.","authors":"Yasemin Yavuz, Sedef Kotanli, Mehmet S Dogan, Zelal Almak","doi":"10.17219/acem/194504","DOIUrl":"https://doi.org/10.17219/acem/194504","url":null,"abstract":"<p><strong>Background: </strong>Pulpal vitality is important for the tooth to maintain its physiological function and preserve its structure.</p><p><strong>Objectives: </strong>The aim of this study was to evaluate the clinical and radiographic 6- and 12-month treatment success of calcium hydroxide (CH) and calcium silicate materials in indirect pulp treatment (IPT) and direct pulp capping (DPC) in teeth with deep dentin decay.</p><p><strong>Material and methods: </strong>The study included 143 teeth of patients aged 17-69 years with no systemic disease. The study is grouped under 3 main groups (Dycal, Biodentine, TheraCal PT). Direct pulp capping was applied to 65 teeth and IPT to 66 teeth. All teeth were restored with Universal adhesive system and Universal composite (G-Premio Bond; GC Corp., Tokyo, Japan).</p><p><strong>Results: </strong>In the statistical evaluations of the data obtained, 0.05 was accepted as the level of statistical significance. The general success rate in the IPT group was found to be 95.2% for Biodentine (Septodont, SaintMaur-des-Fossés, France), 91.7% for Dycal (Dentsply/Caulk, International Inc. Milford, USA) and 90.1% for TheraCal PT (Bisco Inc., Schaumburg, USA) at both 6 and 12 months. When the clinical and radiographic success was compared at 6 months and 12 months, no statistically significant difference was determined between the materials (p > 0.05). In the clinical and radiographic evaluations at the end of 6-month follow-up in the DPC group, the success rates were determined to be 96.0% for Biodentine, 81.8% for Dycal and 63.2% for TheraCal PT. At 12 months, these rates were 96.0% for Biodentine, 68.2% for Dycal and 63.2% for TheraCal PT. DPC Biodentine was found to be the most successful material (96.0%).</p><p><strong>Conclusions: </strong>At the end of the 12-month follow-up period, it was considered that the 3 materials (Biodentine, Dycal, TheraCal) can be selected for IPT. In DPC, Biodentine was found to be more successful than both calcium silicate containing resin and CH.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143389659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Squamous and basal skin cancers in 17,207 solid organ transplant recipients: Real-world data from national health insurance database in Poland.","authors":"Wojciech M Wysocki, Aleksandra Kulbat, Karolina Richter, Marta Krzysztofik, Marta Kołodziej-Rzepa, Tomasz Wojewoda","doi":"10.17219/acem/199653","DOIUrl":"https://doi.org/10.17219/acem/199653","url":null,"abstract":"<p><strong>Background: </strong>Immunosuppressive therapy in organ transplant ensures proper graft function for many years, but it is burdened with a negative impact on the development of skin cancer in them.</p><p><strong>Objectives: </strong>To characterize the impact of immunosuppressive therapy in transplant recipients on the development of non-melanoma skin cancers (NMSC).</p><p><strong>Material and methods: </strong>A total of 17,207 Polish patients who underwent liver, heart or kidney transplants between 2010 and 2022 and were on immunosuppression were included in the study. Immunosuppression was most commonly achieved using a regimen of tacrolimus (TAC) or cyclosporine A (CsA) combined with mycophenolic acid (MPA) and glucocorticosteroids (GS). Data on NMSC incidence from the National Health Fund in this population were analyzed and compared against incidence of NMSC in general Polish population in the same period.</p><p><strong>Results: </strong>Renal transplant recipients demonstrated a significantly elevated risk of NMSC compared to the general population, with a 1-year cumulative incidence of 0.09% vs 0.04% (p < 0.001), a 5-year incidence of 1.21% vs 0.18% (p < 0.001) and a 10-year incidence of 4.18% vs 0.36% (p < 0.001). Liver transplant recipients exhibited an elevated risk for the development of NMSC, which persisted and increased over time (incidence of 0.09% vs 0.04% at 1 year (p < 0.001), 0.83% vs 0.18% at 5 years (p < 0.001) and 2.65% vs 0.36% at 10 years (p < 0.001)). Heart transplant recipients also showed a significantly higher cumulative incidence of NMSC at 1 year (0.09% vs 0.04%, p < 0.001), 5 years (0.89% vs 0.18%, p < 0.001) and 10 years (4.06% vs. 0.36%, p < 0.001) post-transplantation.</p><p><strong>Conclusions: </strong>Organ transplant recipients have an 2 times at 1 year, 4,5 times after 5 years and 9 times after 10 years increased risk of NMSC on average as opposed to general Polish population in the same period.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143254509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Which risk factors are involved in a distal biceps tendon injury? A systematic review.","authors":"Markus Jaschke, Łukasz Kołodziej, Aleksandra Wilk, Marek Droździk","doi":"10.17219/acem/187891","DOIUrl":"10.17219/acem/187891","url":null,"abstract":"<p><p>Distal biceps tendon rupture is a rare injury predominately occurring in middle-aged men. This study aimed to collect relevant risk factors associated with distal biceps tendon rupture from the published literature. This systematic review aimed to collect and tabulate the risk factors for distal biceps tendon rupture. Studies published in English were searched concerning risk factors for distal biceps tendon ruptures until July 2022; cohort studies, case series and randomized controlled trials were subjected to analysis. Case studies, cadaveric studies and reviews in any form were excluded. The studies were quantitatively and qualitatively reviewed. One hundred twenty-one articles presenting risk factors for distal biceps tendon ruptures were identified, recruiting a total of 7,484-7,576 patients. The average age of the individuals was 46.8 years, with 96.7% being males and 94.7% having affinity for sports activities. In 56.7% of the cases, the dominant arm was involved, and in 54.6%, the right arm was affected. The use of tobacco was found in 20.8% of cases and of anabolic steroids in 2.5% of cases. On average, 55.8% of distal biceps tendon rupture patients had a physical occupation and the most common mechanism of the injury was related to heavy weight lifting observed in 53.2% of subjects. The most common and outstanding reported risk factors for distal biceps tendon ruptures were age, sex and sports activity, i.e., middle-aged males being still physically active and practicing sports. Steroid usage does not seem to increase significantly the risk of the distal biceps tendon rupture.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"257-268"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Withania somnifera and Trigonella foenum-graecum as ingredients of testosterone-boosting supplements: Possible clinical implications.","authors":"Monika Skrzypiec-Spring, Andrzej Pokrywka, Justyna Kuliczkowska-Płaksej, Adam Szeląg, Marek Bolanowski","doi":"10.17219/acem/185743","DOIUrl":"10.17219/acem/185743","url":null,"abstract":"<p><p>This narrative review provides an overview of scientific studies on dietary supplements that may affect circulating testosterone (T) levels to explore which substances are scientifically proven to increase T concentration. We also review the scientific literature for their potential mechanisms and laboratory test changes triggered by their use. Based on the analysis of existing data on substances used to increase endogenous T levels, especially double-blind placebo-controlled randomized clinical trials, we selected 2 herbal extracts with the best documented positive effects on T levels, Withania somnifera root and root extracts/leaves and seed extracts of Trigonella foenum-graecum. Although these substances have different postulated mechanisms of action, both significantly increase T levels in men. Withania somnifera may inhibit the effects of cortisol and prolactin on the hypothalamic-pituitary-gonadal axis and directly affect the hypothalamus. Trigonella foenum-graecum seeds contain the active substance diosgenin, which is a precursor for sex hormone synthesis in gonads.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"295-303"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140846824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence-based healthcare: Bridging the gap between research and practice.","authors":"Aleksandra Królikowska, Robert Prill, Miloslav Klugar","doi":"10.17219/acem/201184","DOIUrl":"10.17219/acem/201184","url":null,"abstract":"<p><p>The establishment of the first JBI Affiliated group in Poland at Wroclaw Medical University marks a significant advancement in evidence-based healthcare (EBHC) nationally. This editorial explores the evolution of EBHC and the critical role of JBI in driving its progress. Founded in 1996 as a research institute at the Royal Adelaide Hospital in South Australia and now based at the University of Adelaide, JBI has emerged as an international leader in evidence synthesis, transfer and implementation. Its Feasibility, Appropriateness, Meaningfulness, and Effectiveness (FAME) framework highlights the feasibility, appropriateness, meaningfulness, and effectiveness of healthcare practices, ensuring that decisions are patient-centered and contextually relevant. JBI's global collaboration network encompasses over 85 entities, with 23 located in Europe, emphasizing the importance of cultural inclusivity and international partnerships. Recent initiatives include translating the JBI Model of into Polish, German and Czech, linking global knowledge to local contexts, and enhancing understanding for professionals and students alike. This editorial also underscores the collaborative achievements of JBI entities in Wroclaw, Brandenburg an der Havel, Prague, and Olomouc. These partnerships have propelled regional implementation, research and education, fostering a shared vision for elevating healthcare quality. Launching a new EBHC section in the Advances in Clinical and Experimental Medicine journal is a significant step forward, inviting global contributions and stimulating innovation and knowledge sharing in EBHC. The presence of a JBI Affiliated group at Wroclaw Medical University symbolizes a transformative commitment to excellence and collaboration. It sets new benchmarks for healthcare in Poland and beyond while reinforcing the global mission of evidence-based practice.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"139-147"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143405342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An update on cardiovascular disorders in systemic lupus erythematosus.","authors":"Ewa Pędzich, Adrian Bednarek, Julita Młynarska, Emilia Włoszek, Dominika Klimczak-Tomaniak, Karolina Gumiężna, Adam Piasecki, Adam Rdzanek, Grażyna Sygitowicz, Marcin Grabowski, Mariusz Tomaniak","doi":"10.17219/acem/184868","DOIUrl":"10.17219/acem/184868","url":null,"abstract":"<p><p>Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a complex multifactorial etiology that develops as a result of autoimmune processes, leading to widespread inflammation and malfunction of multiple tissues and organs, and, as a consequence, triggers arterial hypertension, conduction disorders, valvular heart disease, pulmonary hypertension (PH), and venous thromboembolism events (VTE), contributing to increased mortality. Moreover, autoimmune abnormalities can accelerate atherogenesis and lead to many SLE manifestations, including coronary artery disease (CAD) and cerebrovascular events. The current review aimed to systematize existing data from the latest works and summarize published guidelines and recommendations. In particular, the prevalence of cardiovascular disorders in SLE patients, advances in diagnostics (including imaging methods and biomarker laboratory testing), the possible future direction of therapy, and the latest European Alliance of Associations for Rheumatology (EULAR) guidelines for optimal management of cardiovascular risk in SLE were overviewed.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"269-281"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140100768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum fibroblast growth factor 19 level correlates inversely with clinical and endoscopic activity of inflammatory bowel disease.","authors":"Agata Łukawska, Agata Mulak","doi":"10.17219/acem/184132","DOIUrl":"10.17219/acem/184132","url":null,"abstract":"<p><strong>Background: </strong>Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a chronic condition with relapsing-remitting course. Diarrhea and abdominal pain are the most common IBD symptoms. Fibroblast growth factor 19 (FGF19) is an endocrine factor that inhibits hepatic bile acid production and may be used as a diagnostic marker for bile acid malabsorption.</p><p><strong>Objectives: </strong>To assess serum FGF19 levels in active and inactive phases of IBD and find a potential correlation between FGF19 and disease activity.</p><p><strong>Material and methods: </strong>Fasting serum FGF19 levels were measured in 105 IBD patients (47 UC patients, 41 CD patients without previous ileocecal resection (NR-CD), 17 CD patients after ileocecal resection (IR-CD), and 17 control subjects). The disease activity was assessed using clinical, laboratory and endoscopic criteria.</p><p><strong>Results: </strong>Inverse correlations were found between FGF19 level and intensity of diarrhea (in UC), abdominal pain intensity (in UC and IR-CD) and inflammatory markers (in UC and IR-CD). Moreover, FGF19 concentration was inversely correlated with clinical and endoscopic activity indices in UC and CD.</p><p><strong>Conclusions: </strong>Fluctuations in FGF19 level related to clinical and endoscopic activity of UC and CD revealed a clear pattern of higher values in remission than in active disease phases. Fibroblast growth factor 19 may serve as a potential diagnostic biomarker and constitute a new therapeutic target in IBD.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"187-198"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An artificial intelligence model for Lhermitte's sign in patients with pediatric-onset multiple sclerosis: A follow-up study.","authors":"Hasan A Uysal, Turan Poyraz, Halil Gulluoglu, Fethi Idiman, Egemen Idiman","doi":"10.17219/acem/196466","DOIUrl":"10.17219/acem/196466","url":null,"abstract":"<p><strong>Background: </strong>Lhermitte's sign (LS) is an important clinical marker for patients with multiple sclerosis (MS). Research on pediatric-onset MS (POMS) and LS is limited. To date, there has been no research conducted on the clinical and artificial intelligence (AI)-based radiological correlation of LS.</p><p><strong>Objectives: </strong>This follow-up study aims to investigate the relationship between LS and clinical findings according to AI-based radiological characteristics of patients with POMS.</p><p><strong>Material and methods: </strong>Basic descriptive statistics of patients with POMS according to sociodemographic, clinical and radiological findings were collected. Variables were evaluated at a 95% confidence level (95% CI), and a value of p < 0.05 was accepted as statistically significant. The LS in patients with MS was classified according to its presence in the past and at the time of the study screening: group A: absent; group B: positive in the past but absent at screening; group C: present both in the past and at the screening; group D: absent in the past but present at the screening. In addition, patients were grouped according to the duration of their MS, with the following classifications: <10 years and at least 10 years.</p><p><strong>Results: </strong>A total of 1,298 records were identified in the database search. Ninety-two patients who met the inclusion criteria were included in the study. The frequency of upper cervical lesions (C1-4 vertebral segmental levels) was higher in group B and C than in group A (p = 0.017). Among patients with an MS duration of 10-years, C1-4 lesions were least frequent in group A.</p><p><strong>Conclusions: </strong>Spinal imaging with AI-based programs can be used at least as much as brain magnetic resonance imaging (MRI) for early diagnosis, prognosis and treatment response. We have for the first time investigated LS in a large sample of patients with POMS. It is, however, recommended to conduct further multicenter studies to more specifically identify LS in patients with POMS.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"165-177"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143405261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic pain in the elderly: A constant challenge.","authors":"Małgorzata I Sobieszczańska","doi":"10.17219/acem/200647","DOIUrl":"10.17219/acem/200647","url":null,"abstract":"<p><p>Chronic pain is a common, long-standing and bitter experience affecting a huge percentage of the still increasing elderly population. Owing to the multifactorial etiopathology and complex clinical presentation with a lot of severe consequences, management of the permanent pain should be varied and tailored to the particular patient. This approach comprises multimodal pharmacotherapy, including all analgesics and adjuvants, likewise selected interventions, physical therapy and rehabilitation, as well psychological counselling.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"149-151"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143405333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review and meta-analysis of serum cystatin C levels and acute ischemic stroke outcomes.","authors":"Chenguang Hao, Shibao Chen","doi":"10.17219/acem/184641","DOIUrl":"10.17219/acem/184641","url":null,"abstract":"<p><p>Acute ischemic stroke (AIS) has a high rate of death and causes long-term disability, leading to a global economic burden annually. Therefore, discovering biomarkers to improve AIS patient prognosis is critical. Previous studies reported an association between serum cystatin C (CysC) levels and outcomes in AIS patients, but the results remain controversial. This systematic review and meta-analysis aimed to explore the relationship between serum CysC and AIS patient outcomes using currently available studies. The literature search included PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP, and Wan Fang databases. Outcomes included poor functional recovery, cognitive dysfunction and death. Weighted mean difference (WMD) with 95% confidence interval (95% CI) was used as an effect index for measurement data. Results demonstrated that serum CysC was significantly higher in AIS patients with poor functional recovery (WMD = 0.18, 95% CI: 0.08-0.28), cognitive dysfunction (WMD = 0.16, 95% CI: 0.09-0.23) and death (WMD = 0.32, 95% CI: 0.02-0.62) than in the control groups when follow-up time was <1 month. These findings show that high serum CysC levels were associated with poor AIS patient outcomes. Further studies are needed to examine whether reducing serum CysC can prevent poor outcomes in AIS patients.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"153-163"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140183489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}